The May 2006 issue of the Journal of Pharmacology and Experimental Therapeutics stated that Italy’s Instuto di Chemica Biomolecolare assessed the anti-cancer activity of various non-psychoactive cannabinoids – including cannabidiol (CBD), cannabigerol (CBG), and cannabichromine (CBC) – in vivo and in vitro. The outcome was that the CBD was more potent as a cancer cell growth inhibitor than other cannabinoids. {{{o}}} In addition, they were surprised to find thsat the coumpound was excellent in stopping the spread of breast cancer cells by causing apoptosis (programmed cell death) to occur.
Prior studies have determined that cannabinoids can reduce the size of brain tumors as well as stop the spreading of these tumors both in animal and humans. Cannabigerol and CBC, even though they lack the strength of CBD, contain antitumor properties.
Other preclinical studies have shown that cannabinoids an halt cancer cell growth and selectively trigger malignant death of cancer cells, jung cancer cells and leukemic cells to name a few.
